



Corrigendum: Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis

OPEN ACCESS

Approved by:

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Peng Pu
pp841103@sina.com
Quan He
851557800th@sina.com

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 17 October 2021

Accepted: 25 October 2021

Published: 11 November 2021

Citation:

Shi H, Tang H, Ai W, Zeng Q, Yang H,
Zhu F, Wei Y, Feng R, Wen L, Pu P and
He Q (2021) Corrigendum: Schisandrin
B Antagonizes Cardiotoxicity Induced
by Pirarubicin by Inhibiting
Mitochondrial Permeability Transition
Pore (mPTP) Opening and Decreasing
Cardiomyocyte Apoptosis.
Front. Pharmacol. 12:796551.
doi: 10.3389/fphar.2021.796551

Hongwei Shi^{1,2†}, Heng Tang^{3†}, Wen Ai⁴, Qingfu Zeng⁵, Hong Yang⁶, Fengqing Zhu³,
Yunjie Wei⁷, Rui Feng³, Li Wen³, Peng Pu^{3*} and Quan He^{3*}

¹Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China, ³Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, ⁴Shenzhen Nanshan District People's Hospital, Shenzhen, China, ⁵Department of Vascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁶Department of Endocrine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, ⁷Department of Cardiology, Hubei Shiyan Taihe Hospital, Shiyan, China

Keywords: schisandrin B, cardiotoxicity, anti-apoptotic pirarubicin, anti-apoptotic, THP

A Corrigendum on

Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis by Shi, H., Tang, H., Ai, W., Zeng, Q., Yang, H., Zhu, F., Wei, Y., Feng, R., Wen, L., Pu, P., and He, Q. (2021) *Front. Pharmacol.* 12:733805. doi: 10.3389/fphar.2021.733805

In the original article, there was an error in the Funding section. We neglected to include “National Key R&D Program of China (Grant numbers: 2018YFC1311400, 2018YFC1311404)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Shi, Tang, Ai, Zeng, Yang, Zhu, Wei, Feng, Wen, Pu and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.